Sinclair Research Appoints Sandra Love as Director of Safety Pharmacology

Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology. In this role, Dr. Love will lead Sinclair’s Safety Pharmacology program and consult on the design and development of in vivo pharmacology disease models to support current and prospective customers.

“My key focus is to optimize and expand Sinclair’s safety pharmacology service offerings to support both core battery assessments as well as the evaluation of effects on renal and gastrointestinal systems,” Dr. Love said. “With fewer CROs than ever offering full-service IND-enabling toxicology and safety pharmacology services, I am excited to be part of a growing team with a standalone telemetry facility that can generate high fidelity safety pharmacology data to support our sponsors’ programs.”

For over 20 years, Dr. Love has specialized in providing safety pharmacology research services to small and large biopharmaceutical drug developers. Prior to joining Sinclair Research, Sandra was Director of Pharmacology at Charles River (formerly CitoxLab USA and Xenometrics) where she oversaw the safety pharmacology program, providing guidance on study designs to sponsors and supervising all functions and personnel for the pharmacology group.

Dr. Love holds a BS in Biology from the University of Missouri - Columbia and a PhD in Pharmaceutical Sciences from the University of Missouri - Kansas City. She has co-authored multiple research papers published in peer-reviewed scientific journals and has been an active member of the Safety Pharmacology Society since its inception in 2001.

“Sandra brings a depth and breadth of safety pharmacology experience to Sinclair,” said Andy Brown, Vice President of Commercial Operations at Sinclair Research. “Her experience leading core battery safety pharmacology assessments and expanded GI and renal evaluations will be invaluable as we support an increasingly diverse array of drug development programs for our growing customer base. I’m excited for the continued growth of Sinclair’s safety pharmacology program and how it will create value for our customers as they seek a high quality nonclinical CRO to support their research.”

About Sinclair Research

Sinclair Research, a nonclinical contract research organization (CRO), offers animal efficacy models, pharmacokinetics/pharmacodynamics evaluation, and IND-enabling toxicology and safety pharmacology research capabilities to support biopharmaceutical, animal health and medical device development programs. Sinclair is experienced in all research models and is the leading expert in miniature swine research. Built on more than 50 years of experience, Sinclair has emerged as a leader in diabetes, dermal, otic and animal health research services with streamlined quality systems supporting both VICH and GLP-compliant studies and SEND reporting with no backlog.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005578/en/